<p>This study presents the single-step synthesis of a variety of 3-phenylimidazo[1,2-<i>a</i>]pyridine derivatives <b>1–24</b> by reacting different phenacyl bromides with 2-aminopyridine in the presence of DABCO (1,4-diazabicyclo[2.2.2]octane) as a base. Compounds were characterized by spectroscopic techniques to confirm their structures. All synthetic derivatives were evaluated against important metabolic drug targets, including human carbonic anhydrase I and II, <i>α</i>-glucosidase, and <i>α</i>-amylase enzymes. Pertinent to mention that all the synthetic analogs revealed potent inhibitory strength with K<sub>i</sub> values in the range of 104.36—439.41 nM against hCA-I and 119.46—472.35 nM against hCA-II in comparison with the standard acetazolamide K<sub>i</sub> = 466.53 ± 41.22 nM (for hCA-I) and K<sub>i</sub> = 481.18 ± 33.05 nM (for hCA-II). All compounds showed potent inhibitory activity against <i>α</i>-glucosidase enzyme with IC<sub>50</sub> value 247.50—784.32&#xa0;nM, compared to the standard acarbose = 22,800&#xa0;nM. In addition, compounds were also identified as potent inhibitors of <i>α</i>-amylase with an IC<sub>50</sub> value of 342.67–1011.53&#xa0;nM compared to the standard acarbose = 10,000&#xa0;nM. In silico studies of the potential compounds <b>8</b>, <b>13</b>, <b>15</b>, <b>19</b>, <b>20</b>, and <b>21</b> against hCA-I, hCA-II, <i>α</i>-glycosidase, and <i>α</i>-amylase were performed to assess the enzyme–ligand interactions with the residues of the active-site target enzymes.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Design, synthesis, and biological evaluation of 3-phenylimidazo[1,2-a]pyridine derivatives as diverse enzyme inhibitors

  • Muhammad Ali,
  • Khalid Mohammed Khan,
  • Parham Taslimi,
  • Shahbaz Shamim,
  • Uzma Salar,
  • Tugba Taskin-Tok,
  • Syed Muhammad Saad,
  • Muhammad Taha

摘要

This study presents the single-step synthesis of a variety of 3-phenylimidazo[1,2-a]pyridine derivatives 1–24 by reacting different phenacyl bromides with 2-aminopyridine in the presence of DABCO (1,4-diazabicyclo[2.2.2]octane) as a base. Compounds were characterized by spectroscopic techniques to confirm their structures. All synthetic derivatives were evaluated against important metabolic drug targets, including human carbonic anhydrase I and II, α-glucosidase, and α-amylase enzymes. Pertinent to mention that all the synthetic analogs revealed potent inhibitory strength with Ki values in the range of 104.36—439.41 nM against hCA-I and 119.46—472.35 nM against hCA-II in comparison with the standard acetazolamide Ki = 466.53 ± 41.22 nM (for hCA-I) and Ki = 481.18 ± 33.05 nM (for hCA-II). All compounds showed potent inhibitory activity against α-glucosidase enzyme with IC50 value 247.50—784.32 nM, compared to the standard acarbose = 22,800 nM. In addition, compounds were also identified as potent inhibitors of α-amylase with an IC50 value of 342.67–1011.53 nM compared to the standard acarbose = 10,000 nM. In silico studies of the potential compounds 8, 13, 15, 19, 20, and 21 against hCA-I, hCA-II, α-glycosidase, and α-amylase were performed to assess the enzyme–ligand interactions with the residues of the active-site target enzymes.